S&P 500   4,594.93 (+1.37%)
DOW   35,450.54 (+1.20%)
QQQ   372.99 (+1.78%)
AAPL   169.22 (+1.80%)
MSFT   310.01 (+2.20%)
FB   326.76 (+2.24%)
GOOGL   2,746.21 (+1.62%)
AMZN   3,142.27 (+0.52%)
TSLA   1,040.10 (+4.46%)
NVDA   254.34 (+1.46%)
BABA   134.41 (+5.22%)
NIO   30.77 (+7.47%)
AMD   126.90 (-1.07%)
CGC   8.08 (+5.76%)
MU   89.84 (-0.18%)
GE   101.48 (+0.85%)
T   27.35 (+0.26%)
F   22.81 (+1.60%)
DIS   152.25 (+1.43%)
AMC   19.20 (+4.80%)
PFE   53.56 (+0.04%)
ACB   5.09 (+4.73%)
BA   221.37 (+1.98%)
S&P 500   4,594.93 (+1.37%)
DOW   35,450.54 (+1.20%)
QQQ   372.99 (+1.78%)
AAPL   169.22 (+1.80%)
MSFT   310.01 (+2.20%)
FB   326.76 (+2.24%)
GOOGL   2,746.21 (+1.62%)
AMZN   3,142.27 (+0.52%)
TSLA   1,040.10 (+4.46%)
NVDA   254.34 (+1.46%)
BABA   134.41 (+5.22%)
NIO   30.77 (+7.47%)
AMD   126.90 (-1.07%)
CGC   8.08 (+5.76%)
MU   89.84 (-0.18%)
GE   101.48 (+0.85%)
T   27.35 (+0.26%)
F   22.81 (+1.60%)
DIS   152.25 (+1.43%)
AMC   19.20 (+4.80%)
PFE   53.56 (+0.04%)
ACB   5.09 (+4.73%)
BA   221.37 (+1.98%)
S&P 500   4,594.93 (+1.37%)
DOW   35,450.54 (+1.20%)
QQQ   372.99 (+1.78%)
AAPL   169.22 (+1.80%)
MSFT   310.01 (+2.20%)
FB   326.76 (+2.24%)
GOOGL   2,746.21 (+1.62%)
AMZN   3,142.27 (+0.52%)
TSLA   1,040.10 (+4.46%)
NVDA   254.34 (+1.46%)
BABA   134.41 (+5.22%)
NIO   30.77 (+7.47%)
AMD   126.90 (-1.07%)
CGC   8.08 (+5.76%)
MU   89.84 (-0.18%)
GE   101.48 (+0.85%)
T   27.35 (+0.26%)
F   22.81 (+1.60%)
DIS   152.25 (+1.43%)
AMC   19.20 (+4.80%)
PFE   53.56 (+0.04%)
ACB   5.09 (+4.73%)
BA   221.37 (+1.98%)
S&P 500   4,594.93 (+1.37%)
DOW   35,450.54 (+1.20%)
QQQ   372.99 (+1.78%)
AAPL   169.22 (+1.80%)
MSFT   310.01 (+2.20%)
FB   326.76 (+2.24%)
GOOGL   2,746.21 (+1.62%)
AMZN   3,142.27 (+0.52%)
TSLA   1,040.10 (+4.46%)
NVDA   254.34 (+1.46%)
BABA   134.41 (+5.22%)
NIO   30.77 (+7.47%)
AMD   126.90 (-1.07%)
CGC   8.08 (+5.76%)
MU   89.84 (-0.18%)
GE   101.48 (+0.85%)
T   27.35 (+0.26%)
F   22.81 (+1.60%)
DIS   152.25 (+1.43%)
AMC   19.20 (+4.80%)
PFE   53.56 (+0.04%)
ACB   5.09 (+4.73%)
BA   221.37 (+1.98%)
OTCMKTS:RNUGF

ReNeuron Group Stock Forecast, Price & News

$0.61
0.00 (0.00%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.61
$0.61
50-Day Range
$0.61
$1.49
52-Week Range
$0.60
$1.96
Volume
N/A
Average Volume
2,167 shs
Market Capitalization
$19.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-21.95
30 days | 90 days | 365 days | Advanced Chart
Receive RNUGF News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.


ReNeuron Group logo

About ReNeuron Group

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RNUGF
Previous Symbol
NASDAQ:RNUGF
CIK
N/A
Fax
N/A
Employees
62
Year Founded
N/A

Sales & Book Value

Annual Sales
$340 thousand
Book Value
$0.78 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$19.42 million
Optionable
Not Optionable

Company Calendar

Today
1/20/2022
Fiscal Year End
3/31/2022

MarketRank

Overall MarketRank

0.98 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












ReNeuron Group (OTCMKTS:RNUGF) Frequently Asked Questions

How has ReNeuron Group's stock price been impacted by Coronavirus?

ReNeuron Group's stock was trading at $1.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RNUGF stock has decreased by 65.1% and is now trading at $0.61.
View which stocks have been most impacted by COVID-19
.

Are investors shorting ReNeuron Group?

ReNeuron Group saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 700 shares, an increase of 75.0% from the November 30th total of 400 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 7.0 days.
View ReNeuron Group's Short Interest
.

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebo, CEO & Director (Age 56, Pay $548.93k)
  • Ms. Suzanne Hancock, Head of Operations
  • Dr. Stefano Pluchino, Chief Scientific Officer
  • Mr. Shaun Stapleton, Head of Regulatory Affairs and VP of Regulatory Affairs & Pharmacovigilance
  • Dr. Richard L. Beckman, Chief Medical Officer

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the OTCMKTS under the ticker symbol "RNUGF."

How do I buy shares of ReNeuron Group?

Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ReNeuron Group's stock price today?

One share of RNUGF stock can currently be purchased for approximately $0.61.

How much money does ReNeuron Group make?

ReNeuron Group has a market capitalization of $19.42 million and generates $340 thousand in revenue each year.

How many employees does ReNeuron Group have?

ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

Where are ReNeuron Group's headquarters?

ReNeuron Group is headquartered at Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-20-3819-8400.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.